遏制巴基斯坦丙型肝炎病毒流行:扩大治疗与预防对实现消除目标的影响
研究建立巴基斯坦HCV传播模型并校准至2007年全国调查、注射吸毒者调查及献血者数据,预测至2030年HCV负担及不同干预情景。若不扩大治疗,慢性HCV患病率将从3.9%升至5.1%,年新发感染从70万增至110万,并发生140万HCV相关死亡。实现WHO 2030消除目标需大幅扩大DAA治疗与预防。
要点
- 无进一步治疗时,2016-2030年慢性HCV患病率从3.9%升至5.1%,年新发感染从70万增至110万。
- 实现WHO 2030消除目标,若无预防扩大和优先治疗,需每年88万DAA治疗。
核心结论
- 巴基斯坦需大幅扩大HCV预防和治疗干预以实现WHO消除目标,否则HCV负担将显著增加。
研究设计与样本
- 建立HCV传播模型,校准至2007年全国调查、注射吸毒者调查和献血者数据;当前治疗覆盖数据来自专家意见和已发表报告。
主要发现
- 无进一步治疗(当前每年约15万治疗)时,2016-2030年慢性HCV患病率从3.9%升至5.1%,年新发感染从70万增至110万,发生140万HCV相关死亡。
- 无预防扩大和优先治疗时,实现WHO 2030消除目标需每年88万DAA治疗。
- 治疗优先向肝硬化患者(年治疗80%)和PWID(治疗率为非PWID两倍)时,年治疗数降至75万。
关键数值与推荐
- WHO HCV消除目标:2030年HCV发病率降低80%,HCV相关死亡率降低65%。
- 无预防扩大和优先治疗时,需每年88万DAA治疗。
- 治疗优先向肝硬化患者(年治疗80%)和PWID(治疗率为非PWID两倍)时,年治疗数降至75万。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The World Health Organization (WHO) has developed a global health strategy to eliminate viral hepatitis. We project the treatment and prevention requirements to achieve the WHO HCV elimination target of reducing HCV incidence by 80% and HCV-related mortality by 65% by 2030 in Pakistan, which has the second largest HCV burden worldwide. METHODS: We developed an HCV transmission model for Pakistan, and calibrated it to epidemiological data from a national survey (2007), surveys among people who inject drugs (PWID), and blood donor data. Current treatment coverage data came from expert opinion and published reports. The model projected the HCV burden, including incidence, prevalence and deaths through 2030, and estimated the impact of varying prevention and direct-acting antiviral (DAA) treatment interventions necessary for achieving the WHO HCV elimination targets. RESULTS: With no further treatment (currently ∼150 000 treated annually) during 2016-30, chronic HCV prevalence will increase from 3.9% to 5.1%, estimated annual incident infections will increase from 700 000 to 1 100 000, and 1 400 000 HCV-associated deaths will occur. To reach the WHO HCV elimination targets by 2030, 880 000 annual DAA treatments are required if prevention is not scaled up and no treatment prioritization occurs. By targeting treatment toward persons with cirrhosis (80% treated annually) and PWIDs (double the treatment rate of non-PWIDs), the required annual treatment number decreases to 750 000. If prevention activities also halve transmission risk, this treatment number reduces to 525 000 annually. CONCLUSIONS: Substantial HCV prevention and treatment interventions are required to reach the WHO HCV elimination targets in Pakistan, without which Pakistan's HCV burden will increase markedly.
引用
- Lim AG, Qureshi H, Mahmood H, et al. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination. Int J Epidemiol. 2018. PMID: 29309592. doi:10.1093/ije/dyx270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。